Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.

MLA

Jordan, Stanley C., et al. “Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.” Kidney International Reports, vol. 7, no. 4, Feb. 2022, pp. 720–31. EBSCOhost, https://doi.org/10.1016/j.ekir.2022.01.1074.

APA

Jordan, S. C., Ammerman, N., Choi, J., Huang, E., Najjar, R., Peng, A., Sethi, S., Sandhu, R., Atienza, J., Toyoda, M., Ge, S., Lim, K., Gillespie, M., Zhang, X., Haas, M., & Vo, A. (2022). Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. Kidney International Reports, 7(4), 720–731. https://doi.org/10.1016/j.ekir.2022.01.1074

Chicago

Jordan, Stanley C, Noriko Ammerman, Jua Choi, Edmund Huang, Reiad Najjar, Alice Peng, Supreet Sethi, et al. 2022. “Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts.” Kidney International Reports 7 (4): 720–31. doi:10.1016/j.ekir.2022.01.1074.